Metotreksat Ebewe (Methotrexate Disodium)

Methotrexate Disodium blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a co‑factor needed for DNA, RNA and protein synthesis. By limiting nucleotide formation, it slows the proliferation of rapidly dividing cells and also increases adenosine release, which contributes to its anti‑inflammatory properties.

The specific dose of Metotreksat Ebewe is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Healthcare professionals tailor the regimen to achieve optimal efficacy while minimizing potential toxicity, and patients should follow the exact instructions provided by their prescriber.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause fetal malformations and loss. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after stopping the drug. Breastfeeding is also not recommended, as methotrexate can be excreted in milk.

To request Metotreksat Ebewe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Metotreksat Ebewe delivers the same active ingredient, methotrexate disodium, as other branded or generic methotrexate formulations. Differences may lie in manufacturing standards, packaging, and regulatory approvals. Compared with biologic agents, methotrexate is generally less expensive but may require more laboratory monitoring for safety.

Metotreksat Ebewe should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Ensure that the container is tightly closed and keep it out of reach of children.

The product is supplied as an injectable preparation and can be given by intramuscular, intravenous or subcutaneous injection, according to the prescriber’s instructions. Administration is performed by a qualified healthcare professional in a clinical setting, using aseptic technique and appropriate dosing equipment.

Serious adverse events include bone‑marrow suppression leading to pancytopenia, severe infections, pulmonary toxicity such as interstitial pneumonitis, significant liver injury (fibrosis or cirrhosis), renal failure, and life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be educated to report any signs of infection, respiratory difficulty, jaundice or unusual skin changes promptly.

Metotreksat Ebewe is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate or its excipients, and patients with severe renal or hepatic impairment that cannot be corrected. Caution is also advised for those with active infections, uncontrolled immune disorders, or who are receiving other potent immunosuppressive agents.